Prescription of antidepressants is increased in Danish patients with polycystic ovary syndrome and is associated with hyperandrogenism. A population-based cohort study

Clinical Endocrinology

Volumn 80, Issue 6, 2014, Pages 884-889

  Altinok, M L ^a   Glintborg, D ^a   Depont Christensen, R ^b   Hallas, J ^b   Andersen, M ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERTENSION; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY HEALTH CARE; YOUNG ADULT; ADOLESCENT; CASE CONTROL STUDY; COHORT ANALYSIS; DENMARK; METHODOLOGY; POLYCYSTIC OVARY SYNDROME; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGY; QUALITY OF LIFE;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; FEMALE; HUMANS; HYPERANDROGENISM; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RESEARCH DESIGN; YOUNG ADULT;

EID: 84899587526     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12365     Document Type: Article

References (23)

1. Glintborg, D., &, Andersen, M., (2010) An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecological Endocrinology, 4, 281-296.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 1, 19-25.
3. Wild, R.A., Carmina, E., Amanti-Kandarakis, E., et al,. (2010) Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a position statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism, 5, 2038-2049.
4. Velling, M.L., Mumm, H., Andersen, M., et al,. (2011) Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertility and Sterility, 5, 1275-1280.
5. Cinar, N., Kizilarslanoglu, M.C., Harmanci, A., et al,. (2011) Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Human Reproduction, 12, 3339-3345.
6. Hahn, S., Janssen, O.E., Tan, S., et al,. (2005) Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. European Journal of Endocrinology, 6, 853-860.
7. Jones, G.L., Hall, J.M., Balen, A.H., et al,. (2008) Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Human Reproduction Update, 1, 15-25.
8. Wilson, S., Sharp, C.A., &, Davie, M.W., (2012) Health-related quality of life in patients with osteoporosis in the absence of vertebral fracture: a systematic review. Osteoporosis International, 12, 2749-2768.
9. Dokras, A., Clifton, S., Futterweit, W., et al,. (2011) Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstetrics and Gynecology, 1, 145-152.
10. Zhuang, J., Wang, X., Xu, L., et al,. (2013) Antidepressants for polycystic ovary syndrome. Cochrane Database Systematic Review, 5, CD008575.
11. Glintborg, D., Henriksen, J.E., Andersen, M., et al,. (2004) Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertility and Sterility, 6, 1570-1579.
12. Ferriman, D., &, Gallwey, J.D., (1961) Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology, PMID: 13892577.
13. Nielsen, T.L., Hagen, C., Wraae, K., et al,. (2007) Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. Journal of Clinical Endocrinology and Metabolism, 7, 2696-2705.
14. Teede, H., Deeks, A., &, Moran, L., (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine, 8, 41.
15. Glintborg, D., Mumm, H., Ravn, P., et al,. (2012) Age associated differences in prevalence of individual rotterdam criteria and metabolic risk factors during reproductive age in 446 Caucasian women with polycystic ovary syndrome. Hormone and Metabolic Research, 9, 694-698.
16. Ganie, M.A., Laway, B.A., Wani, T.A., et al,. (2011) Association of subclinical hypothyroidism and phenotype, insulin resistance, and lipid parameters in young women with polycystic ovary syndrome. Fertility and Sterility, 6, 2039-2043.
17. Greenage, M., Kulaksizoglu, B., Cilingiroglu, M., et al,. (2011) The role of anxiety and emotional stress as a risk factor in treatment-resistant hypertension. Current Atherosclerosis Reports, 2, 129-131.
18. Hallas, J., (1996) Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology, 5, 478-484.
19. Cinar, N., Harmanci, A., Demir, B., et al,. (2012) Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Human Reproduction, 6, 1840-1845.
20. Escobar- Morreale, H.F., (2010) Diagnosis and management of hirsutism. Annals of the New York Academy of Sciences, PMID: 20840269.
21. Stewart, P.M., Shackleton, C.H., Beastall, G.H., et al,. (1990) 5 alpha-reductase activity in polycystic ovary syndrome. Lancet, 8687, 431-433.
22. Schule, C., (2007) Neuroendocrinological mechanisms of actions of antidepressant drugs. Journal of Neuroendocrinology, 3, 213-226.
23. Hayes, R.M., Wu, P., Shelton, R.C., et al,. (2012) Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. American Journal of Obstetrics and Gynecology, 1, 49.